Immix Biopharma (IMMX) Accumulated Expenses (2020 - 2026)
Quarterly results put Accumulated Expenses at $880671.0 for Q1 2026, up 20.34% from a year ago — trailing twelve months through Mar 2026 was $880671.0 (up 20.34% YoY), and the annual figure for FY2025 was $942163.0, up 43.15%.
Immix Biopharma has reported Accumulated Expenses over the past 7 years, most recently at $880671.0 for Q1 2026.
- Accumulated Expenses reached $880671.0 in Q1 2026 per IMMX's latest filing, down from $942163.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $942163.0 in Q4 2025 and bottomed at $9407.0 in Q1 2022.
- Median Accumulated Expenses over the past 5 years was $577854.0 (2023), compared with a mean of $535147.6.
- The largest annual shift saw Accumulated Expenses rose 13.9% in 2024 before it soared 311.75% in 2025.
- Over 5 years, Accumulated Expenses stood at $9407.0 in 2022, then soared by 6042.81% to $577854.0 in 2023, then rose by 13.9% to $658161.0 in 2024, then soared by 43.15% to $942163.0 in 2025, then decreased by 6.53% to $880671.0 in 2026.
- Business Quant data shows Accumulated Expenses for IMMX at $880671.0 in Q1 2026, $942163.0 in Q4 2025, and $438243.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 880,671.00 |
| Dec 31, 2025 | 942,163.00 |
| Sep 30, 2025 | 438,243.00 |
| Jun 30, 2025 | 702,579.00 |
| Mar 31, 2025 | 731,794.00 |
| Dec 31, 2024 | 658,161.00 |
| Sep 30, 2024 | 198,095.00 |
| Jun 30, 2024 | 170,632.00 |
| Mar 31, 2024 | 577,025.00 |
| Dec 31, 2023 | 577,854.00 |
| Mar 31, 2022 | 9,407.00 |
| Dec 31, 2021 | 9,099.00 |
| Dec 31, 2020 | 342,837.00 |